Puracyp, Inc. Company Profile

07:59 EST 12th December 2018 | BioPortfolio

Puracyp began operations in 1993 focusing on the distribution of monospecific inhibitory antibodies to several human P450 enzymes. Members of the pharmaceutical industry used these antibodies to assess the contribution of a single P450 enzyme to a drug metabolizing reaction. Researchers also used anti-human P450 immunoglobulins in Western blotting experiments to determine expression of individual enzymes in human liver microsomes. Puracyp now offers cell lines to assess induction of the major drug metabolizing enzymes and P-glycoprotein. Results from studies in these cell lines mimic those conducted in isolated human hepatocyte preparations.Puracyp is dedicated to providing cell lines for rapidly determining the ability of chemicals to enhance the expression of drug metabolizing enzymes and transporters. We specialize in the development and application of such cells for in vitro techniques to determine the effects of xenobiotics on the human drug metabolizing enzymes. These applications can be used to assess induction of specific human enzymes and transporters. The primary focus of Puracyp is to offer a high volume screening service. Puracyp's service utilizes stably integrated cell lines harboring P450 enhancer elements in reporter gene constructs. Transcriptional activation by chemicals/drugs can be assessed by determining reporter gene activity. Use of these cell lines results in a timely and cost efficient system conducive to high throughput. Cell lines currently available include those expressing the CYP3A4 enhancer, those with the p-glycoprotein enhancer and those that can be used to identify Ah receptor mediated induction of genes containing the dioxin response element (DRE). Future plans are to develop animal cell lines to assist in alleviating the large number of animals used in the preclinical stages of drug development.
Puracyp also licenses its cell lines to companies to perform in-house induction analyses. In the past year, Puracyp has licensed to tebu-biosciences Laboratories enabling distribution of Puracyp's cell lines and screening services to European companies.


1989 Palomar Oaks Way, Suite B
United States of America


Phone: 760-929-9508
Fax: 760-929-9834

News Articles [0 Results]


Drugs and Medications [0 Results]


PubMed Articles [0 Results]


Clinical Trials [0 Results]


Companies [1 Associated Companies listed on BioPortfolio]

Puracyp, Inc.

Puracyp began operations in 1993 focusing on the distribution of monospecific inhibitory antibodies to several human P450 enzymes. Members of the pharmaceutical industry used these antibodies to asses...

More Information about "Puracyp, Inc." on BioPortfolio

We have published hundreds of Puracyp, Inc. news stories on BioPortfolio along with dozens of Puracyp, Inc. Clinical Trials and PubMed Articles about Puracyp, Inc. for you to read. In addition to the medical data, news and clinical trials, BioPortfolio also has a large collection of Puracyp, Inc. Companies in our database. You can also find out about relevant Puracyp, Inc. Drugs and Medications on this site too.

Quick Search


Relevant Topics

Enzymes are proteins that catalyze (i.e., increase the rates of) chemical reactions. In enzymatic reactions, the molecules at the beginning of the process, called substrates, are converted into different molecules, called products. Almost all chemical re...

Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...

Hepatology is the study of liver, gallbladder, biliary tree, and pancreas, and diseases associated with them. This includes viral hepatitis, alcohol damage, cirrhosis and cancer. As modern lifestyles change, with alcoholism and cancer becoming more promi...

Corporate Database Quicklinks

Searches Linking to this Company Record